Current Rheumatology Reports

, 13:409

Mucosal Inflammation in Spondylarthritides: Past, Present, and Future

  • Liesbet Van Praet
  • Filip Van den Bosch
  • Herman Mielants
  • Dirk Elewaut
Article

DOI: 10.1007/s11926-011-0198-2

Cite this article as:
Van Praet, L., Van den Bosch, F., Mielants, H. et al. Curr Rheumatol Rep (2011) 13: 409. doi:10.1007/s11926-011-0198-2

Abstract

Spondylarthritides (SpA) and inflammatory bowel disease (IBD) are idiopathic, chronic inflammatory disorders. Although they are very distinct and well-defined entities, there is clinical and genetic evidence supporting some degree of overlap between the pathogenesis of the two. Subclinical gut inflammation is present in up to two thirds of all SpA patients and can evolve into IBD. This subclinical gut inflammation has been shown to be strongly associated with joint inflammation, providing a clue for a common pathophysiologic background. Despite extensive research progress in the field over the past few years, many questions remain unanswered. In this paper, we focus on the clinical, genetic, and pathophysiologic overlap of SpA and IBD. Furthermore, we discuss some of the targets that may influence therapeutic decision making.

Keywords

Spondylarthritides Mucosal inflammation Inflammatory bowel disease IBD Gut inflammation Crohn’s disease Ankylosing spondylitis Arthritis Sulfasalazine Cytokines Tumor necrosis factor-alpha Interleukin HLA-B27 

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  • Liesbet Van Praet
    • 1
  • Filip Van den Bosch
    • 1
  • Herman Mielants
    • 1
  • Dirk Elewaut
    • 1
  1. 1.Department of RheumatologyGhent University HospitalGhentBelgium

Personalised recommendations